Stock Traders Purchase High Volume of Call Options on Stoke Therapeutics (NASDAQ:STOK)

Stoke Therapeutics, Inc. (NASDAQ:STOK) was the recipient of some unusual options trading activity on Friday. Stock investors purchased 10,008 call options on the company. This represents an increase of 1,407% compared to the average daily volume of 664 call options.

Stoke Therapeutics Price Performance

Shares of STOK traded up $0.83 during trading hours on Friday, hitting $28.76. The stock had a trading volume of 118,917 shares, compared to its average volume of 909,724. Stoke Therapeutics has a 12 month low of $5.35 and a 12 month high of $38.69. The firm has a market capitalization of $1.64 billion, a PE ratio of 42.93 and a beta of 1.32. The stock has a fifty day moving average price of $27.41 and a 200 day moving average price of $18.21.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.54) by ($0.11). Stoke Therapeutics had a return on equity of 13.28% and a net margin of 19.73%.The business had revenue of $10.63 million during the quarter, compared to the consensus estimate of $6.06 million. As a group, analysts anticipate that Stoke Therapeutics will post -2.01 EPS for the current fiscal year.

Insider Buying and Selling

In other Stoke Therapeutics news, insider Barry Ticho sold 5,931 shares of the business’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $25.72, for a total transaction of $152,545.32. Following the completion of the sale, the insider directly owned 7,195 shares of the company’s stock, valued at approximately $185,055.40. The trade was a 45.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Adrian R. Krainer sold 40,472 shares of the company’s stock in a transaction on Friday, November 14th. The stock was sold at an average price of $26.98, for a total value of $1,091,934.56. Following the sale, the director owned 364,246 shares of the company’s stock, valued at $9,827,357.08. This trade represents a 10.00% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 213,367 shares of company stock worth $5,110,464 over the last 90 days. Company insiders own 9.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Generali Investments Management Co LLC bought a new stake in shares of Stoke Therapeutics during the 3rd quarter valued at $41,000. BNP Paribas Financial Markets raised its holdings in shares of Stoke Therapeutics by 66.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after acquiring an additional 1,668 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in Stoke Therapeutics by 461.0% during the second quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock valued at $50,000 after purchasing an additional 3,591 shares during the last quarter. AlphaQuest LLC bought a new position in shares of Stoke Therapeutics in the 1st quarter valued at about $72,000. Finally, US Bancorp DE boosted its holdings in shares of Stoke Therapeutics by 9,743.9% in the 1st quarter. US Bancorp DE now owns 11,222 shares of the company’s stock worth $75,000 after purchasing an additional 11,108 shares during the period.

Wall Street Analyst Weigh In

STOK has been the subject of several research analyst reports. Chardan Capital raised Stoke Therapeutics to a “strong-buy” rating in a research report on Wednesday. Wedbush boosted their target price on shares of Stoke Therapeutics from $22.00 to $32.00 and gave the company an “outperform” rating in a report on Wednesday, November 5th. Weiss Ratings restated a “hold (c-)” rating on shares of Stoke Therapeutics in a research report on Wednesday. Needham & Company LLC increased their price objective on Stoke Therapeutics from $22.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, October 10th. Finally, Canaccord Genuity Group raised their price target on Stoke Therapeutics from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Stoke Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $31.00.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.